- Home
- WFG vs TVTX Comparison
WFG vs TVTX Comparison
Compare WFG & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFG | TVTX |
|---|---|---|
| Founded | 1955 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.3B |
| IPO Year | 2007 | 2013 |
Fundamental Metrics
Financial Performance| Metric | WFG | TVTX |
|---|---|---|
| Price | $66.34 | $57.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $89.50 | $40.62 |
| AVG Volume (30 Days) | 176.1K | ★ 1.4M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.05 | $44.76 |
| Revenue Next Year | $10.26 | $35.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.34 | $15.03 |
| 52 Week High | $76.99 | $60.10 |
Technical Indicators
Market Signals| Indicator | WFG | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 57.47 |
| Support Level | $63.55 | $53.93 |
| Resistance Level | $67.13 | $59.89 |
| Average True Range (ATR) | 2.05 | 2.58 |
| MACD | -0.40 | -0.48 |
| Stochastic Oscillator | 15.22 | 55.36 |
Price Performance
Historical ComparisonAbout WFG West Fraser Timber Co. Ltd.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.